Nord/LB Reiterates €74.40 Price Target for STADA Arzneimittel (SAZ)

Nord/LB set a €74.40 ($88.57) price target on STADA Arzneimittel (ETR:SAZ) in a research report released on Wednesday morning. The firm currently has a sell rating on the stock.

A number of other equities research analysts have also recently issued reports on SAZ. Commerzbank set a €66.25 ($78.87) price objective on STADA Arzneimittel and gave the stock a sell rating in a research note on Tuesday, August 22nd. Independent Research set a €76.00 ($90.48) price objective on STADA Arzneimittel and gave the stock a sell rating in a research note on Tuesday, August 29th. Warburg Research set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a sell rating in a research note on Wednesday. Finally, S&P Global set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a sell rating in a research note on Friday, November 10th. Four investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The company presently has a consensus rating of Sell and an average price target of €74.08 ($88.18).

Shares of STADA Arzneimittel (ETR:SAZ) opened at €88.00 ($104.76) on Wednesday. STADA Arzneimittel has a 12 month low of €46.31 ($55.13) and a 12 month high of €89.21 ($106.20). The stock has a market capitalization of $5,490.00 and a P/E ratio of 57.89.

ILLEGAL ACTIVITY NOTICE: “Nord/LB Reiterates €74.40 Price Target for STADA Arzneimittel (SAZ)” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/24/nordlb-reiterates-74-40-price-target-for-stada-arzneimittel-saz.html.

About STADA Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit